Evidence map›Paper›PMID 41417118›Full record

ReviewEuropean radiology2026

Progressive pulmonary fibrosis.

Ramey Bajwa, Drew Lancaster, Sujal R Desai, Peter M George

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Ramey BajwaDepartment of Interstitial Lung Disease, Royal Brompton Hospital, London, UK. rameybajwa@gmail.com.ORCID http://orcid.org/0000-0001-5933-5751
Drew LancasterHealth Science Center College of Medicine, The University of Tennessee, Knoxville, TN, USA.
Sujal R DesaiDepartment of Radiology, Royal Brompton Hospital, London, UK.
Peter M GeorgeDepartment of Interstitial Lung Disease, Royal Brompton Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A significant number of non-idiopathic pulmonary fibrosis (IPF) cases follow an 'IPF-like' trajectory, known as progressive pulmonary fibrosis (PPF). PPF is associated with increased mortality. One of the criteria for identifying PPF is progression of fibrosis despite conventional treatment on serial high-resolution computed tomography. Progression may be identified by an increased overall extent of fibrosis on CT. However, an increased severity with the same overall extent should also be identified as progression. Radiologists play a critical role in the management of patients with PPF, as the accurate identification of radiological progression may allow patients to commence antifibrotic drugs, which have been shown to significantly reduce subsequent decline in lung function. KEY POINTS: Question Non-idiopathic pulmonary fibrosis (IPF) disease can follow an 'IPF-like' trajectory, known as progressive pulmonary fibrosis (PPF), which is associated with increased mortality. Findings One criterion for PPF is radiological progression, characterised by an increased overall extent or an increaed severity with the same overall extent. Clinical relevance Radiologists play a critical role in identifying PPF, which may allow patients to commence antifibrotic drugs.

Indexed as

Pulmonary FibrosisTomography, X-Ray ComputedDisease ProgressionHumansIdiopathic Pulmonary FibrosisLungAntifibroticsComputed tomographyNintedanibProgressive pulmonary fibrosisRadiological progression of fibrosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.